Briacell Average Receivables from 2010 to 2024

BCTX Stock  USD 0.54  0.02  3.41%   
Briacell Therapeutics Average Receivables yearly trend continues to be fairly stable with very little volatility. Average Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, Briacell Therapeutics Average Receivables regression line of annual values had r-squared of  0.43 and arithmetic mean of  84,208. View All Fundamentals
 
Average Receivables  
First Reported
2010-12-31
Previous Quarter
333.8 K
Current Value
350.5 K
Quarterly Volatility
140.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 86.7 K, Interest Expense of 0.0 or Other Operating Expenses of 34.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Briacell Therapeutics Correlation against competitors.

Latest Briacell Therapeutics' Average Receivables Growth Pattern

Below is the plot of the Average Receivables of Briacell Therapeutics Corp over the last few years. It is Briacell Therapeutics' Average Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Average Receivables10 Years Trend
Slightly volatile
   Average Receivables   
       Timeline  

Briacell Average Receivables Regression Statistics

Arithmetic Mean84,208
Geometric Mean19,111
Coefficient Of Variation166.90
Mean Deviation108,716
Median18,338
Standard Deviation140,541
Sample Variance19.8B
Range369.6K
R-Value0.65
Mean Square Error12.2B
R-Squared0.43
Significance0.01
Slope20,569
Total Sum of Squares276.5B

Briacell Average Receivables History

2024350.5 K
2023333.8 K
2022370.9 K
201818.3 K
2017 2800.58
2016 4135.37
2015 1334.79

About Briacell Therapeutics Financial Statements

Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' Average Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Average Receivables333.8 K350.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.